Accutane/Generics Risk Program Should Include Mandatory Follow-Up Survey
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee suggests enhancements to Roche's SMART program to better prevent pregnancies. The proposal calls for a shared brand/generic system for patient registration.